Sylvie Pilote

Mrs. Sylvie Pilote

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2017 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BDBenoit Drolet
Benoit Drolet
SPSylvie Pilote
Sylvie Pilote
CGCarolanne Gélinas
Carolanne Gélinas
AKAlida-Douce Kamaliza
Alida-Douce Kamaliza
ABAudrey Blais-Boilard
Audrey Blais-Boilard
CSChantale Simard
Chantale Simard
Arachidonic acid can be metabolized by cytochrome P450 (CYP450) enzymes in a tissue- and cell-specific manner to generate vasoactive products such as epoxyeicosatrienoic acids (EETs-cardioprotective) and hydroxyeicosatetraenoic acids (HETEs-cardiotoxic). Type II diabetes is a well-recognized risk factor for developing cardiovascular disease. A mouse model of Type II diabetes (C57BLKS/J-db/db) was used. After sacrifice, livers and hearts were collected, washed, and snap frozen. Total proteins were extracted. Western blots were performed to assess cardiac CYP2J and hepatic CYP2C, CYP4A, and CYP4F protein expression, respectively. Significant decreases in relative protein expression of cardiac CYP2J and hepatic CYP2C were observed in Type II diabetes animals compared to controls (CYP2J: 0.80 ± 0.03 vs. 1.05 ± 0.06, n = 20, p < 0.001); (CYP2C: 1.56 ± 0.17 vs. 2.21 ± 0.19, n = 19, p < 0.01). In contrast, significant increases in relative protein expression of both hepatic CYP4A and CYP4F were noted in Type II diabetes mice compared to controls (CYP4A: 1.06 ± 0.09 vs. 0.18 ± 0.01, n = 19, p < 0.001); (CYP4F: 2.53 ± 0.22 vs. 1.10 ± 0.07, n = 19, p < 0.001). These alterations induced by Type II diabetes in the endogenous pathway (CYP450) of arachidonic acid metabolism may increase the risk for cardiovascular disease by disrupting the fine equilibrium between cardioprotective (CYP2J/CYP2C-generated) and cardiotoxic (CYP4A/CYP4F-generated) metabolites of arachidonic acid.

1 March 2012 in Pharmacological Research
Verified
Journal Article
Closed access
BCBertrand Caillier
Bertrand Caillier
SPSylvie Pilote
Sylvie Pilote
DPDany Patoine
Dany Patoine
XLXavier Levac
Xavier Levac
CCChristian Couture
Christian Couture
BDBenoit Drolet
Benoit Drolet

11 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Atziri Corin Chavez AlvarezAtziri Corin Chavez Alvarez
Atziri Corin Chavez Alvarez
CBChahrazed Bouzriba
Chahrazed Bouzriba
VOVincent Ouellette
Vincent Ouellette
MGMathieu Gagné-Boulet
Mathieu Gagné-Boulet
APAlexandre Patenaude
Alexandre Patenaude
Sébastien FortinSébastien Fortin
Sébastien Fortin
Background/Objectives: Chemoresistance of breast cancers (BCs) is a major impediment to current chemotherapeutics that urges the development of new drugs and new therapeutic approaches. To that end, phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) were recently prepared to fulfill some of the unmet needs with classic chemotherapeutics. PAIB-SOs are prodrugs bioactivated into potent antimitotics by the cytochrome P450 1A1 (CYP1A1), which is a frequent enzyme in resistant BC cells, but mostly missing in normal cells. Our screening program studies of PAIB-SO chemolibraries selected three prototypical PAIB-SOs as antimitotic prodrugs amenable for studies using BC animal models. Methods: Healthy female CD1® IGS mice were treated with three prototypical PAIB-SOs, namely CEU-835, -934, and -938, for the determination of their toxicity and half-lives. Moreover, MCF7 tumor-bearing CD1-Foxn1nu Nude female mice were treated with the three prototypical PAIB-SOs for the determination of their antitumor activity. Results: Herein, we show that multi-intravenous administrations of CEU-835, -934, and -938 at their maximal solubilities are well tolerated in healthy female CD1® IGS mice, as depicted by the evaluation of distress behaviors, organ necropsy, total blood cell count, and histology. Moreover, the half-life of CEU-835, -934, and -938 administered intravenously in healthy CD1® IGS female mice were 8.1, 23.2, and 21.5 h, respectively. Finally, their intravenous administrations of CEU-934 and -938 decreased MCF7 tumor growth as efficiently as paclitaxel in MCF7 tumor-bearing CD1-Foxn1nu Nude mouse model. Conclusions: overall, our study demonstrated for the first time that pentyl-bearing PAIB-SOs are new CYP1A1-dependent prodrugs efficiently decrease breast cancer tumor growth, and show no side effects at their pharmacological concentration in mouse models.

12 August 2026 in Biomed
Verified
Journal Article
Open access
PDF file
APAlexandra Porlier
Alexandra Porlier
SPSylvie Pilote
Sylvie Pilote
BDBenoit Drolet
Benoit Drolet
ICIsabelle Cloutier
Isabelle Cloutier
AVAudrey Vachon
Audrey Vachon
CSChantale Simard
Chantale Simard
Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.